Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNCB74 in Advanced Solid Tumors
NCT06774963Phase 1Recruiting
- Sponsor
- LigaChem Biosciences
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LNCB74 in ovarian cancer, breast cancer, endometrial cancer (EC) and 2 more (2 arms), sponsored by LigaChem Biosciences. Primary endpoints: Safety and Tolerability of LNCB74 at 24 months and Recommended Phase 2 Dose at 24 months. Started Jan 2025; status: recruiting.
02
Drugs
LNCB74
03
Conditions
ovarian cancerbreast cancerendometrial cancer (EC)non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT06774963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06774963.